TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) and QT Imaging (NASDAQ:QTI – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, risk, valuation, dividends and profitability.
Valuation and Earnings
This table compares TriSalus Life Sciences and QT Imaging”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TriSalus Life Sciences | $45.15 million | 6.19 | -$39.23 million | ($1.30) | -3.49 |
| QT Imaging | $18.92 million | 1.90 | -$21.08 million | ($1.57) | -1.67 |
Insider & Institutional Ownership
2.6% of TriSalus Life Sciences shares are held by institutional investors. Comparatively, 24.2% of QT Imaging shares are held by institutional investors. 16.3% of TriSalus Life Sciences shares are held by insiders. Comparatively, 25.4% of QT Imaging shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares TriSalus Life Sciences and QT Imaging’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TriSalus Life Sciences | -62.59% | N/A | -64.47% |
| QT Imaging | -77.25% | -1,202.69% | -46.76% |
Analyst Recommendations
This is a summary of current ratings and recommmendations for TriSalus Life Sciences and QT Imaging, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TriSalus Life Sciences | 1 | 1 | 3 | 0 | 2.40 |
| QT Imaging | 1 | 1 | 1 | 0 | 2.00 |
TriSalus Life Sciences presently has a consensus target price of $10.20, suggesting a potential upside of 124.92%. Given TriSalus Life Sciences’ stronger consensus rating and higher probable upside, equities analysts plainly believe TriSalus Life Sciences is more favorable than QT Imaging.
Summary
TriSalus Life Sciences beats QT Imaging on 8 of the 13 factors compared between the two stocks.
About TriSalus Life Sciences
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
About QT Imaging
QT Imaging Holdings, Inc. engages in the research, development, and commercialization of body imaging systems for detection, diagnosis, monitoring, and treatment of diseases. The company offers QT Ultrasound Breast Scanner, an ultrasonic imaging system that provides reflection-mode and transmission-mode images of a patient’s breast. QT Imaging Holdings, Inc. was founded in 2011 and is based in Novato, California.
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
